Eyepoint, Inc. · NASDAQ:EYPT
Eyepoint — EyePoint Pharmaceuticals — Investor Presentation (November 2019)
28 slides from Eyepoint's investor presentation, Nov 27, 2019
Slide 1: Investor Presentation November 2019
Investor Presentation November 2019 NASDAQ: EYPT Exhibit 99.1
Slide 2: Safe Harbor Statements
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. This presentation is intended for communication for investors only. Noth
Slide 3: An Emerging Leader in Ophthalmology
An Emerging Leader in Ophthalmology Launched YUTIQ® (Feb 4, 2019) and DEXYCU® (Mar 12, 2019) (Permanent and unique J codes for DEXYCU and YUTIQ in place) Strategic focus to become go-to partner for commercialization in ophthalmology Chronic non-infectious uveitis affecting the posterior segment of t
Slide 4: Ophthalmology Product Pipeline
Ophthalmology Product Pipeline Program Preclin. Phase 1 Phase 2 Phase 3 Commercial Rights DEXYCU® - post-operative inflammation WW YUTIQ® three-year treatment for chronic non-infectious uveitis affecting the posterior segment U.S.(1) YUTIQ® 50 (sNDA) 6-month treatment for chronic non-infectious uvei
Slide 5: Durasert and Verisome: Proven, FDA Approved Technologies
Durasert™ Verisome™ Durasert™ and Verisome™: Proven, FDA Approved Technologies Ocular insert for long-term delivery of small molecules Approved products: YUTIQ® (2018, EyePoint) ILUVIEN® (2012, Alimera) - DME RETISERT ® (2005, B&L) – Uveitis VITRASERT® (1996, B&L) -CMV retinitis Microsphere suspensi
Slide 6: 2019: A Transformational Year
2019: A Transformational Year YUTIQ® 50 (6-month) regulatory pathway reviewed with FDA with approval pathway clarified EYP-1901 - Durasert™ TKI for wet-AMD advanced into IND enabling studies Durasert™ and Verisome® technologies positioned for partnering and organic pipeline growth Multiple product o
Slide 7: Two Commercial Products Launched in 2019
Two Commercial Products Launched in 2019 Postoperative inflammation following ocular surgery Chronic non-infectious uveitis affecting the posterior segment of the eye 33 dedicated KAMs targeting high-volume ambulatory surgical centers (ASCs) Permanent and specific J-Code with minimal reimbursement i
Slide 8: DEXYCU Market: U.S. Cataract Surgery
* Based upon company estimates for 2018. Source: imaged from the American Optometric Association. DEXYCU® Market U.S. Cataract Surgery Intraocular lens is inserted Intraocular lens is positioned Diseased lens is removed Cataract Surgeries in 2018 4.8 Million* 8% annual growth rate in the U.S. Most p
Slide 9: DEXYCU Market Opportunity
* Source: Vigamox/Besivance product labeling (not specifically indicated for this use, but are commonly prescribed for use). ** Source: Prolensa/Bromday product labeling (not specifically indicated for this use, but are commonly prescribed for use). DEXYCU Market Opportunity Post-cataract treatment
Slide 10: DEXYCU: First and Only Single-dose Intracameral Steroid
1 Wong V. et al. Pharmacokinetic Study of 10090 in the Anterior Chamber of Rabbits (2013). Note: Refer to the full DEXYCU® product label at www.eyepointpharma.com. DEXYCU® Detectable up to 22 days after single injection(1) Suspension placed behind the iris First and Only FDA-approved Single-dose, Su
Slide 11: DEXYCU Demonstration
DEXYCU Demonstration Please see video at company website: https://eyepointpharma.com/case-study-series/
Slide 12: DEXYCU Sales Process
DEXYCU® Sales Process 1. Introduce Introduce DEYXCU and its clinical and safety data to target physician 2. Educate Educate the ASC where physician operates about DEXYCU profile 3. Sample Schedule a physician and staff DEXYCU trial and training 4. Order ASC places first order and files DEXYCU reimbu
Slide 13: DEXYCU Launch Progress Update
DEXYCU® Launch Progress Update Third Quarter Ended 9/30/19 207% Of all ASCs orders placed in Q3 were repeat orders Increase of customer orders compared to Q2 September 2019 represented the highest volume month for repeat orders to date 37% Of total Q3 order volume from repeat orders 74%
Slide 14: DEXYCU Cumulative Orders Since Launch
Month over month growth accelerating DEXYCU® Cumulative Orders Since Launch DEXYCU® month over month growth of cumulative orders averaged 62.5% in the 3rd quarter
Slide 15: DEXYCU Market Potential Based on Account Penetration
Data based on internal estimates DEXYCU® Market Potential Based on Account Penetration thru 9/30/19 Value of Target Accounts Value of Trained Accounts Value of Current ASC Accounts Ordering Value of Current ASC Accounts with 3+ Orders DEXYCU Market Potential $2.5B DEXYCU ASCs in-serviced to Date $12
Slide 16: DEXYCU Statistically Significant Inflammation Reduction
DEXYCU® Statistically Significant Inflammation Reduction Note: Refer to the full DEXYCU® product label at www.eyepointpharma.com. * *P≤0.05 vs. placebo Day 8 Primary endpoint Placebo (n=80) DEXYCU® (n=156) * * * 3x clearance vs. placebo at day 8 40 percentage point difference vs. placebo (97.5% CI)
Slide 17: DEXYCU IOP Elevation Versus Placebo
% of patients Data on file. Phase III Study 13-04. Post hoc analysis. DEXYCU® IOP Elevation Versus Placebo Not Clinically Significant IOP Intervals on POD 1 IOP Intervals on POD 3 IOP Intervals on POD 8 IOP Intervals on POD 15 % of patients % of patients % of patients
Slide 18: DEXYCU Phase 3 Study Safety Results
Note: Refer to the full DEXYCU® product label at www.eyepointpharma.com. DEXYCU® Phase 3 Study – Safety Results Safety, n (%) Placebo N=80 517 mcg N=156 Any TEAE in Study Eye 51 (63.8) 72 (46.2) Any Ocular SAE in Study Eye 0 0 Any Non-ocular SAE 4 (5.0) 4 (2.6) Study Eye AEs Occurring in ³5% of at L
Slide 19: YUTIQ Market
YUTIQ® Market Patients in the U.S. with Chronic Non-infectious Posterior Segment Uveitis ~55K–120K ~30,000 new cases of blindness per year in the U.S. 3rd leading cause of blindness in the U.S. Uveitis is: Inflammation of the Uveal tract (iris, ciliary body, choroid), or adjacent structures (lens, r
Slide 20: YUTIQ
YUTIQ® YUTIQ® is designed to deliver a sustained release of fluocinolone for patients with chronic noninfectious posterior uveitis for up to 36 months Durasert Technology Packaging YUTIQ Placement
Slide 21: YUTIQ Consistent Micro Dosing of Steroid
YUTIQ® Consistent micro dosing of steroid up to three years Significantly reduces the recurrence of flares that cause blindness Primary Goal of Therapy in Uveitis
Slide 22: YUTIQ Recurrence Rate at Six and Twelve Months
* Sham includes standard of care. Note: Refer to the full YUTIQ® product label at www.eyepointpharma.com YUTIQ® Recurrence Rate at Six and Twelve Months Vs Sham 4.4x 3.1x p < 0.01 p < 0.01 p < 0.01 p < 0.01 YUTIQ Patients more likely to be recurrence free 2.5x 1.8x YUTIQ Patients more likely to be r
Slide 23: YUTIQ Reduced Probability of Uveitis Recurrence Through 36 Months
Note: Sham patients include patients that received rescue therapy. YUTIQ® Single Insert Reduced Probability of Uveitis Recurrence Through 36 Months YUTIQ Median Time to First Recurrence: 1,051 Days 3 years ITT Population
Slide 24: YUTIQ Safety - Select Adverse Events
1. Includes macular edema and cystoid macular edema 2. Includes eye pain and procedural pain 3. Includes hypotony, intraocular pressure decreased and procedural hypotension Note: Refer to the full YUTIQ® product label at www.eyepointpharma.com YUTIQ® Safety – Select Adverse Events Safety, n (%) YUTI
Slide 25: YUTIQ Launch Progress Update
YUTIQ® Launch Progress Update Third Quarter Ended 9/30/19 17% Of customers were repeat customers Increase of customer orders compared to Q2 Continued strong reception of the YUTIQ® product profile from uveitis specialists 53% Of total order volume from repeat orders 85%
Slide 26: YUTIQ Cumulative Orders Since Launch
YUTIQ® Cumulative Orders Since Launch YUTIQ® month over month growth of cumulative orders averaged 22% in the 3rd quarter
Slide 27: Key Access Agreements to Expand Product Reach
Key Access Agreements to Expand Product Reach DEXYCU® and YUTIQ® added to the Federal Supply Schedule Access to U.S. veterans and other federal agencies Nine Million VA beneficiaries added Three-year agreement for DEXYCU® Vizient’s network includes more than 50% of the nation’s acute care providers,
Slide 28: An Emerging Leader in Ophthalmology
An Emerging Leader in Ophthalmology Launched YUTIQ® (Feb 4, 2019) and DEXYCU® (Mar 12, 2019) (Permanent and unique J codes for DEXYCU and YUTIQ in place) Strategic focus to become go-to partner for commercialization in ophthalmology Chronic non-infectious uveitis affecting the posterior segment of t
EyePoint Pharmaceuticals — Investor Presentation (November 2019) on 6ix